acquired
Stage
About
Apellis Pharmaceuticals develops therapies that inhibit the complement system, with lead programs like pegcetacoplan targeting retinal diseases such as geographic atrophy and other complement-mediated disorders.
Explore Apellis Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.